Log in

Relevant bibliographies by topics / CD20 antibodies / Dissertations / Theses

To see the other types of publications on this topic, follow the link: CD20 antibodies.

Dissertations / Theses on the topic 'CD20 antibodies'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 33 dissertations / theses for your research on the topic 'CD20 antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Eve, Heather E. "Lenalidomide and the new-generation anti-CD20 antibodies in mantle cell lymphoma." Thesis, Exeter and Plymouth Peninsula Medical School, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.573119.

Full text

Abstract:

Lenalidomide is a second-generation immunomodulatory drug with clinical activity in mantle cell lymphoma (MCL). In vitro work shows that lenalidomide enhances NK-mediated cytotoxicity against MCL yet the significance of this in vivo remains unproven. Since NK cells are key effectors of antibody-dependent cellular cytotoxicity (ADCC), there is a clear rationale for combining lenalidomide with monoclonal antibodies. However, one concern regarding this is the potential for lenalidomide to downregulate target antigen expression on malignant B Iymphocytes. This thesis presents phase II clinical tri

APA, Harvard, Vancouver, ISO, and other styles

2

Walshe, Claire Anne. "Signalling cascades induced by type I and II anti-CD20 monoclonal antibodies." Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shan, Daming. "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/5682.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

DIAS, CARLA R. de B. R. "Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re." reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Full text

Abstract:

Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0<br>Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0<br>Tese (Doutoramento)<br>IPEN/T<br>Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

APA, Harvard, Vancouver, ISO, and other styles

5

Nolan, David Francis Luke. "The synergistic interaction between CD20 monoclonal antibodies and histone deacetylase inhibitors in B cell Non Hodgkin's Lymphoma." Thesis, University of Southampton, 2010. https://eprints.soton.ac.uk/162661/.

Full text

Abstract:

Recent improvements in molecular sub typing of Non Hodgkin’s lymphomas have resulted in targeted therapies becoming incorporated into treatment paradigms. The anti-CD20 monoclonal antibody, Rituximab, has resulted in dramatic improvements in survival for patients with B cell Non Hodgkin’s lymphoma. Histone deacetylase inhibitors are a novel class of anti cancer agents targeting epigenetic regulation. This thesis addresses the interaction between histone deacetylase inhibitors and anti-CD20 monoclonal antibodies, including Rituximab, both in vitro and in vivo. The initial approach identified sy

APA, Harvard, Vancouver, ISO, and other styles

6

Reslan, Lina. "Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia." Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10346/document.

Full text

Abstract:

CD20 est une cible thérapeutique validée pour l’immunothérapie des néoplasmes lymphoïdesdes cellules B, incluant la Leucémie Lymphoïde Chronique (LLC). Nous avons comparé les effets de rituximab et de GA101 (nouvel anticorps anti-CD20) contre les cellules LLC fraiches in vitro. Le marquage avec Annexine V a démontré une induction de l’apoptose après l’exposition au rituximab et GA101.Contrairement au rituximab, GA101 induisait une réduction du potentiel transmembranaire mitochondrial, uneffet qui peut être partiellement inhibé par la cyclosporine A et qui est partiellement caspase-dépendant. G

APA, Harvard, Vancouver, ISO, and other styles

7

Spasevska, Ivana. "The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1304/document.

Full text

Abstract:

Les anticorps monoclonaux (AcM) anti-CD20 sont essentiels pour le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique (LLC). Les AcM agissent soit en activant directement la signalisation apoptotique dans les cellules cibles, soit via le système immunitaire. Dans une étude préclinique, nous avons montré que le traitement avec AcM anti-CD20, rituximab et GA101, induit l'expression de la protéine early growth response 1 (EGR-1) (Dalle et al., 2011). EGR-1 est un facteur de transcription régulé par le calcium (Ca2+) et CD20 est impliqué dans la régulation du flux calcique

APA, Harvard, Vancouver, ISO, and other styles

8

AKANJI, AKINKUNMI G. "Estudo de marcação com iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma nao-hodgkin." reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11488.

Full text

Abstract:

Made available in DSpace on 2014-10-09T12:52:27Z (GMT). No. of bitstreams: 0<br>Made available in DSpace on 2014-10-09T14:01:38Z (GMT). No. of bitstreams: 0<br>Dissertação (Mestrado)<br>IPEN/D<br>Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP

APA, Harvard, Vancouver, ISO, and other styles

9

Nishida, Michio. "Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions." Kyoto University, 2008. http://hdl.handle.net/2433/124332.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

AKANJI, AKINKUNMI G. "Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos." reponame:Repositório Institucional do IPEN, 2013. http://repositorio.ipen.br:8080/xmlui/handle/123456789/28021.

Full text

Abstract:

Submitted by Pedro Silva Filho (pfsilva@ipen.br) on 2017-11-17T17:17:04Z No. of bitstreams: 0<br>Made available in DSpace on 2017-11-17T17:17:04Z (GMT). No. of bitstreams: 0<br>Linfomas são cânceres que se iniciam a partir da transformação maligna de um linfócito no sistema linfático. Os linfomas são divididos em duas categorias principais: os linfomas de Hodgkin e todos os outros linfomas, denominados linfomas não-Hodgkin (LNH). Os pacientes com LNH são comumente tratados com radioterapia apenas ou combinada com quimioterapia utilizando-se de anticorpo monoclonal anti-CD20, principalmente o

APA, Harvard, Vancouver, ISO, and other styles

11

Marques, Carlos Humberto. "Aspectos fundamentais à implantação da tecnologia de produção de anticorpos monoclonais humanizados com potencial aplicação terapêutica." Instituto de Tecnologia em Imunobiológicos, 2005. https://www.arca.fiocruz.br/handle/icict/5781.

Full text

Abstract:

Submitted by Priscila Nascimento (pnascimento@icict.fiocruz.br) on 2012-11-09T16:36:26Z No. of bitstreams: 1 carlos-humberto-marques.pdf: 2761227 bytes, checksum: cf168e11c904e07038251644b2018901 (MD5)<br>Made available in DSpace on 2012-11-09T16:36:26Z (GMT). No. of bitstreams: 1 carlos-humberto-marques.pdf: 2761227 bytes, checksum: cf168e11c904e07038251644b2018901 (MD5) Previous issue date: 2005-05<br>Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.<br>Os anticorpos

APA, Harvard, Vancouver, ISO, and other styles

12

Carpio, Virna Nowotny. "Associação entre a fração do complemento C4d, anticorpos anti-hla doador específicos e infiltrados de células B em enxertos renais com rejeição." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2012. http://hdl.handle.net/10183/139415.

Full text

Abstract:

Introdução: O fragmento C4d e os anticorpos anti-HLA doador específicos (DSA) são marcadores de resposta humoral em enxertos renais com rejeição, mas o papel das células B nesse processo ainda não é claro. Neste estudo foi avaliada a correlação entre C4d, DSA e células B de enxertos com disfunção e sua associação com aspectos morfológicos, função e sobrevida do rim transplantado. Material e Métodos: A marcação para C4d, células B CD20+ e plasmócitos CD138+ foi realizada por imunoperoxidase em biópsias por indicação de 110 receptores de transplante renal. Positividade para CD20 e CD138 foi defi

APA, Harvard, Vancouver, ISO, and other styles

13

Harvey, Melanie Louise. "CD40 antibodies for the treatment of human malignancy." Thesis, University of Southampton, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274432.

Full text

Abstract:

CD40 is an important antigen involved in immune regulation and anti-CD40 antibody therapies against human CD40 expressing tumours may be particularly advantageous. The antibody could induce tumour response in two ways. Firstly it might have a direct anti-tumour effect and secondly it could 'boost' the immune system to provide a heightened immune response that evades tumour tolerance. This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours including transformed human B cell lines (RL and Daudi), human epithelial cell lines (MG79 [ovarian] and Caski [cervic

APA, Harvard, Vancouver, ISO, and other styles

14

Ilkow, Veronica Franciszka. "Engineering IgE antibodies and CD23 for therapeutic discovery." Thesis, King's College London (University of London), 2018. https://kclpure.kcl.ac.uk/portal/en/theses/engineering-ige-antibodies-and-cd23-for-therapeutic-discovery(54f73d64-5c16-42c4-9dea-42855873eeb6).html.

Full text

Abstract:

Immunoglobulin E (IgE) is fundamental to the allergic response and the functions of IgE are mediated by its Fc region binding to two receptors, FcεRI and CD23 (FcεRII). The interaction of IgE with other proteins have complicated our investigations of the unique role each receptor plays. To solve this, a small-scale library of IgE-Fc proteins was designed with two key positions, one at each receptor-binding site mutated. The unpredictable allosteric nature of IgE prevents rational engineering approaches, thus the design of a membrane-bound IgE-Fc-GFP-tagged protein allowed for the generation of

APA, Harvard, Vancouver, ISO, and other styles

15

Bensalem, Amina. "Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles." Thesis, Tours, 2019. http://www.theses.fr/2019TOUR3302.

Full text

Abstract:

Le rituximab est un anticorps monoclonal (AcMo) IgG1 chimérique qui cible le CD20, une protéine présente à la surface de la plupart des lymphocytes B. Il est indiqué dans la polyarthrite rhumatoïde (PR) et est utilisé dans les vascularites associées aux anticorps (ANCA) anti-cytoplasme des neutrophiles (AAV). Il existe une grande variabilité interindividuelle de la pharmacocinétique (PK) du rituximab et de sa relation concentration-réponse. Le rituximab se lie au CD20, et les complexes rituximab-CD20 formés sont éliminés par le système immunitaire. L’élimination médiée par la cible n'a jamais

APA, Harvard, Vancouver, ISO, and other styles

16

Wright, Tracey Jane. "Characterisation of CD23 cleavage by endogenous and exogenous proteases using neo-epitope antibodies." Thesis, University of Leicester, 2000. http://hdl.handle.net/2381/29820.

Full text

Abstract:

CD23 is the low affinity IgE receptor. It is a type II integral transmembrane glycoprotein that can be shed from the cell surface forming soluble products of approximately 37, 33, 29, 25 and 16kDa. It appears that membrane and soluble CD23 have opposing regulatory functions and that inhibition of CD23 shedding may have potential to alleviate both allergic and inflammatory diseases. This has focused attention on the endogenous protease(s) responsible for CD23 shedding, leading to the demonstration that both the 37 and 33kDA sCD23 fragments are cleaved from the cell surface by a metalloprotease.

APA, Harvard, Vancouver, ISO, and other styles

17

Heath, Andrew. "Assessment of anti- CD40 monoclonal antibodies as novel immunological adjuvants in conjugate vaccines." Thesis, University of Sheffield, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.500260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Prasad, Vijay Narayana Sharma Bhagawati. "Assessment of Anti-CD40 Monoclonal Antibodies as Novel Immunological Adjuvants in Conjuate Vaccines." Thesis, University of Sheffield, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.500680.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Geldart, Thomas Richard. "Efficacy and toxicity of anti-CD40 monoclonal antibodies in the treatment of malignancy." Thesis, University of Southampton, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.403845.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Chan, Ka-kui. "Molecular mechanisms of IL-2 mediated BCL10 nuclear localization and the therapeutic role of an anti-CD25 antibody in nasal NK-cell lymphoma." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B4218244X.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Felonato, Maíra. "Importância da molécula CD28 (molécula co-estimulatória de linfócitos T) na Paracoccidioidomicose pulmonar." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/42/42133/tde-08012008-132539/.

Full text

Abstract:

Como a imunoproteção na Paracoccidioidomicose (PCM) é principalmente mediada por células T, investigamos o impacto da deficiência de CD28, molécula co-estimulatória de linfócitos T, na gravidade da infecção primária e secundária pelo Paracoccidioides brasiliensis. Quando comparados a camundongos C57Bl/6 normais (WT), camundongos CD28-deficientes (CD28KO) apresentaram infecção mais grave associada à produção diminuída de anticorpos e citocinas. Além disso, a pré-imunização de animais deficientes e normais resultou em imunoproteção equivalente. Inesperadamente, a sobrevida de animais CD28KO foi

APA, Harvard, Vancouver, ISO, and other styles

22

Sandin, Linda. "Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-210080.

Full text

Abstract:

Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. T-cells are regarded a major effector cell type in tumor immunotherapy. An important ”switch” needed for T-cell activation involves so-called costimulatory and coinhibitory receptors. In this thesis, experimental tumor models were used to investigate the potential of immunom

APA, Harvard, Vancouver, ISO, and other styles

23

Salgado, Rafael Moysés. "Avaliação do papel do soro imune de camundongos CD28KO (deficiente em IgG especifica) na interação in vivo e in vitro do T. cruzi Sylvio X10/4 com células da linhagem macrofágica." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/42/42133/tde-11072014-135353/.

Full text

Abstract:

As células da linhagem macrofágica são fundamentais na infecção por T. cruzi. Além do reconhecimento por PRRs, a interação com anticorpos e/ou complemento facilita a internalização. Avaliamos o papel in vivo e in vitro de IgM e IgG específicas na saída de parasitas Sylvio X10/4 do sangue, um clone miotrópico de T. cruzi que causa infecção sem parasitemia patente. Devido à sua saída espontânea, estudamos a remoção no sexto dia de infecção, momento em que a parasitemia subpatente aumenta. Camundongos foram infectados e tratados com soro normal (NMS), soro crônico (B6) e soro de animais CD28KO cr

APA, Harvard, Vancouver, ISO, and other styles

24

Chan, Ka-kui, and 陳家駒. "Molecular mechanisms of IL-2 mediated BCL10 nuclear localization and the therapeutic role of an anti-CD25 antibody in nasal NK-celllymphoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B4218244X.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

PIEVANI, ALICE SILVIA. "Cytokine-induced killer (cik) cell cultures for the adoptive immunotherapy of hematological malignancies: characterization and new therapeutic strategies for clinical application." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/20178.

Full text

Abstract:

Cytokine-induced killer (CIK) cells are a heterogeneous population of lymphocytes obtained in vitro within 21 days from mononuclear cells under the influence of cytokines. CIK cells show potent MHC-unrestricted cytotoxicity against a variety of tumor cells, in particular hematological malignancies, and minimal tendency to induce graft-versus-host disease. The expanded bulk CIK culture consists of over 90% CD3+ cells, of which the majority coexpress CD56 and the remaining cells are CD56-. CD3+CD56+ “true” CIK cells are terminally differentiated non dividing lymphocytes which could deliver pote

APA, Harvard, Vancouver, ISO, and other styles

26

Prampero, Anna Carolina. "Produção de anticorpos monoclonais anti-GITR e anti-CD25 através de cultivo de hibridomas e comparação do seu potencial como agentes antitumorais." Universidade Federal de São Carlos, 2017. https://repositorio.ufscar.br/handle/ufscar/9210.

Full text

Abstract:

Submitted by Aelson Maciera (aelsoncm@terra.com.br) on 2017-10-06T18:08:45Z No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5)<br>Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2017-11-28T12:14:39Z (GMT) No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5)<br>Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2017-11-28T12:14:55Z (GMT) No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a

APA, Harvard, Vancouver, ISO, and other styles

27

Kennedy, Adam David. "Enhancing rituximab therapy : analyzing the interaction between rituximab and the human complement pathway /." 2005. http://wwwlib.umi.com/dissertations/fullcit/3189294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

André, Ana Filipa Santos. "Selection of single domain antibodies against the CD20 receptor: a new treatment with potencial anti-tumor properties for B-cell malignancies." Master's thesis, 2016. http://hdl.handle.net/10451/25211.

Full text

Abstract:

Tese de mestrado, Biologia Molecular e Genética, Universidade de Lisboa, Faculdade de Ciências, 2016<br>Lymphoma is the third most common neoplasia in the world. Within lymphomas, non-Hodgkin lymphoma (NHL) is the most common affecting mainly B cells. For more than three decades, chemotherapy and radiotherapy have been the only treatments available, but since the discovery of Rituximab, a new era of lymphoma therapy was inaugurated, once it was the first monoclonal antibody approved against the CD20 receptor. The CD20 receptor is an antigen expressed on the B-cells surface, and it is present n

APA, Harvard, Vancouver, ISO, and other styles

29

Crank, Michelle C. "Understand the mechanism of action of Rutuximab® in the reversal of multidrug resistance in a Non-Hodgkins Lymphoma cell line." 2006. http://edissertations.library.swmed.edu/pdf/CrankM030206/CrankMichelle.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

PIGHI, CHIARA. "Impact of anti-CD20 tumor-targeting therapeutic monoclonal antibodies on human Natural Killer cell responsiveness and plasticity: relevance of FcgammaRIIIA/CD16 affinity ligation conditions." Doctoral thesis, 2018. http://hdl.handle.net/11573/1116013.

Full text

Abstract:

My study is focused on understanding the mechanisms underlying the modulation of NK cell responsiveness and plasticity induced by tumor targeting therapeutic anti-CD20 monoclonal antibodies (mAbs) nowadays routinely used in the treatment of B-cell malignancies and autoimmune disorders. Anti-CD20 mAbs are grouped into type I and II subtypes. Type I mAbs induce CD20 redistribution into lipid rafts and display a remarkable ability to activate complement-dependent cytotoxicity (CDC). On the other hand, type II mAbs, which are not able to localize CD20 complexes into lipid rafts and induce weak or

APA, Harvard, Vancouver, ISO, and other styles

31

Galasso. "MOLECULAR MECHANISMS REGULATING BIOLOGICAL HETEROGENEITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: FROM THE VARIABLE SIGNALING RESPONSE TO CD20 ANTIBODIES AND KINASE INHIBITORS TO THE DIFFERENTIAL EXPRESSION OF CATALASE." Doctoral thesis, 2021. http://hdl.handle.net/11562/1045999.

Full text

Abstract:

La leucemia linfocitaria cronica (LLC) è la forma di leucemia più diffusa nei paesi occidentali con la più alta incidenza tra gli adulti. La LLC rimane una malattia incurabile caratterizzata da un decorso clinico e una risposta al trattamento estremamente variabile. Negli ultimi decenni gli anticorpi monoclonali anti-CD20 (mAbs) hanno rappresentato uno dei progressi più importanti nel trattamento dei disturbi linfoproliferativi, tra cui la LLC. Gli anticorpi terapeutici anti-CD20 sono i più importanti e promettenti partner terapeutici per gli inibitori delle chinasi associate al recettore dell

APA, Harvard, Vancouver, ISO, and other styles

32

Lemos, Francisca Mendes. "Adverse events/mode of action relationship of monoclonal antibodies-based therapies : overview of marketed produts in the European Union." Master's thesis, 2014. http://hdl.handle.net/10451/18333.

Full text

Abstract:

Tese de mestrado, Ciências Biofarmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2014<br>In the past few years, great discoveries and improvements have been done in drug development field and a market that was previously populated just by chemical drugs is now growing to include the so called biopharmaceuticals. As biotechnologically-derived drugs rely on the fundamental understanding of the related disease, it can be predicted that they will play a major – if not dominant – role in the drug development arena of the next decades. Following the success of recombinant proteins, ther

APA, Harvard, Vancouver, ISO, and other styles

33

Chang, Chu-Ting, and 張筑婷. "Study of Natural Products from Cinnamomum kotoense, Arctium lappa and Agave sisalana Regulation Human T Lymphocytes Immune Responses Induced by Anti-CD3 and Anti-CD28 Antibodies." Thesis, 2008. http://ndltd.ncl.edu.tw/handle/47963629530302964174.

Full text

Abstract:

碩士<br>輔仁大學<br>生命科學系碩士班<br>96<br>The immune system is a collection of mechanisms within an organism that protects against disease by identifying and killing pathogens and tumor cells. However, overactive effector immune responses to autologous or allogeneic antigens can result in immune-mediated diseases such as hypersensitivity and autoimmune diseases. One of the therapeutic objectives in autoimmune diseases is blocking of activation, proliferation and cytokine production in T lymphocytes. There are immunosuppressive drugs used for autoimmune diseases, but they almost accompany with serious si

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!